KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) EBITDA Margin: 2009-2024

Historic EBITDA Margin for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to -10.47%.

  • Pacira BioSciences' EBITDA Margin rose 8631.00% to 3.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.80%, marking a year-over-year increase of 1514.00%. This contributed to the annual value of -10.47% for FY2024, which is 2346.00% down from last year.
  • Pacira BioSciences' EBITDA Margin amounted to -10.47% in FY2024, which was down 180.58% from 12.99% recorded in FY2023.
  • Pacira BioSciences' EBITDA Margin's 5-year high stood at 16.61% during FY2021, with a 5-year trough of -10.47% in FY2024.
  • Moreover, its 3-year median value for EBITDA Margin was 9.00% (2022), whereas its average is 3.84%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first soared by 830bps in 2020, then plummeted by 2,346bps in 2024.
  • Over the past 5 years, Pacira BioSciences' EBITDA Margin (Yearly) stood at 10.79% in 2020, then surged by 582bps to 16.61% in 2021, then tumbled by 760bps to 9.00% in 2022, then surged by 399bps to 12.99% in 2023, then slumped by 2,346bps to -10.47% in 2024.